myodine vet 25 mg/ ml
le vet beheer b.v. - nandrolonlaurat - injeksjonsvæske, oppløsning - 25 mg/ ml
ztalmy
marinus pharmaceuticals emerald limited - ganaxolone - epileptic syndromes; spasms, infantile - andre antiepileptics - ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 to 17 years of age. ztalmy may be continued in patients 18 years of age and older.
testosteronundekanoat medical valley 1000 mg/4 ml
medical valley invest ab - testosteronundekanoat - injeksjonsvæske, oppløsning - 1000 mg/4 ml
nebido 1000 mg/4 ml
grünenthal gmbh - testosteronundekanoat - injeksjonsvæske, oppløsning - 1000 mg/4 ml
nebido 1000 mg/4 ml
paranova as (1) - testosteronundekanoat - injeksjonsvæske, oppløsning - 1000 mg/4 ml
andriol 40 mg
merck sharp & dohme b.v. - testosteronundekanoat - kapsel, myk - 40 mg
xtandi
astellas pharma europe b.v. - enzalutamide - prostata neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
nubeqa
bayer ag - darolutamide - prostatic neoplasmer, kastrering-resistant - endokrin terapi - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.
erleada
janssen-cilag international nv - apalutamide - prostata neoplasmer - endokrin terapi - erleada er angitt:i voksne menn for behandling av metastatisk ikke kastrering motstandsdyktig mot prostatakreft (nmcrpc) som har høy risiko for å utvikle metastatisk sykdom. i voksne menn for behandling av metastatisk hormone-sensitive prostatakreft (mhspc) i kombinasjon med androgen mangel terapi (adt).
nebido 1000 mg/4 ml
orifarm as - testosteronundekanoat - injeksjonsvæske, oppløsning - 1000 mg/4 ml